Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: DHRS2 downregulation was significantly associated with poorer prognosis of ESCC. ( a ) The representative pictures of DHRS2 staining in ESCC tumor tissue and paired non-tumor tissue. The boxed regions were magnified and shown in the right panels. ( b ) Kaplan–Meier analysis showed that DHRS2 downregulation was significantly associated with ESCC patients’ poorer survival. ( c ) The relative quantification of DHRS2-V1 and DHRS2-V2 in ESCC cell lines, NE1 (an immortalized human esophageal epithelial cell line) and non-tumor esophageal tissues pool (three cases).

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: Staining

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: Correlation analysis of DHRS2 downregulation with clinicopathologic characteristics of ESCC patients

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques:

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: Univariate and multivariate analysis of different prognostic variables in patients with ESCC

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: Significance Assay

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: DHRS2 suppressed tumor cell growth in vitro and in vivo . ( a ) The relative quantification of DHRS2-V1 and DHRS2-V2 in transfected KYSE30 and KYSE510 cells compared with vector control cells (-Vec) respectively (** P <0.01). ( b , c ) Foci formation assay ( b ) and soft agar assay ( c ) demonstrated that DHRS2-V1 and DHRS2-V2 inhibited the anchorage-dependent and -independent cell growth ability. The results were summarized as mean±s.e.m. of three independent assays (** P <0.01). ( d ) The DHRS2 RNA level decreased in DHRS2 knock-down KYSE180 and HKESC1 (shRNA) cells compared with vector control (c) cells (* P <0.05; ** P <0.01). ( e ) Cell proliferation increased in DHRS2 knock-down cells compared with control cells (* P <0.05). ( f ) Foci formation ability increased in DHRS2 knock-down cells compared with control cells. ( g ) The representative pictures of xenografts formed in nude nice ( n =6). Tumor volume and tumor weight significantly decreased in DHRS2-V1 and DHRS2-V2-transfected KYSE30 cells (** P <0.01). ( h ) The representative pictures of DHRS2 staining of xenograft sections (original magnification: × 200).

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: In Vitro, In Vivo, Transfection, Plasmid Preparation, Tube Formation Assay, Soft Agar Assay, shRNA, Staining

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: DHRS2 inhibited cell motility in vitro and in vivo . ( a ) Wound-healing ability decreased in DHRS2-V1 and DHRS2-V2-transfected KYSE30 cells compared with vector control cells. ( b ) The cell migration and invasion ability decreased in DHRS2-V1 and DHRS2-V2-transfected KYSE30 and KYSE510 cells compared with vector control cells. The results were summarized of three independent assays (* P <0.05; ** P <0.01). ( c ) The cell migration increased in DHRS2 knock-down KYSE180 and HKESC1 cells (shRNA) compared with control cells ( c ) (** P <0.01). ( d ) The size of popliteal lymph nodes decreased in DHRS2-V1 and DHRS2-V2 animal groups compared with vector control group. ( e ) The representative pictures of HE staining of popliteal lymph nodes of the DHRS2-V1, DHRS2-V2 and vector control groups (original magnification: × 200). The boxed regions were magnified as the bottom pictures.

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: In Vitro, In Vivo, Transfection, Plasmid Preparation, Migration, shRNA, Staining

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: DHRS2 affected cell cycle and increased apoptosis. ( a ) The cell distribution was determined by FACS in DHRS2-V1 and DHRS2-V2-transfected KYSE30 and KYSE510 cells compared with vector control cells (* P <0.05). ( b ) Representative pictures of in situ terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick and labeling (TUNEL) assay showed that apoptotic cells increased in DHRS2-V1 and DHRS2-V2-transfected KYSE30 and KYSE510 cells compared with vector control cells. Data were summarized of three independent assays (right) (* P <0.05). ( c ) Apoptotic cells decreased in DHRS2 knock-down KYSE180 cells compared with control cells ( c ). Data was summarized of three independent assays (right).

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: Transfection, Plasmid Preparation, In Situ, Labeling, TUNEL Assay

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: DHRS2 decreased ROS in vitro . ( a ) NADP/NADPH ratio decreased in DHRS2-V1 and DHRS2-V2-transfected KYSE510 cells compared with vector control cells; NADP/NADPH ratio increased in DHRS2 knock-down KYSE180 and HKESC1 cells (* P <0.05; ** P <0.01). ( b ) MitoSox Red staining decreased in DHRS2-V1 and DHRS2-V2-transfected KYSE510 cells compared with vector control cells (original magnification: × 200). ( c ) MitoSox Red staining increased in DHRS2 knock-down KYSE180 and HKESC1 cells compared with control cells ( c ) (original magnification: × 200). ( d ) The mitoSox red staining was quantified by Image J software ( http://rsb.info.nih.gov/ij/ ) and summarized (** P <0.01). ( e ) DNA lesions resulting from ROS were detected in the xenograft sections by immunostaining with 8-oxoG (original magnification: × 200).

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: In Vitro, Transfection, Plasmid Preparation, Staining, Software, Immunostaining

Journal: Oncogene

Article Title: DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma

doi: 10.1038/onc.2017.383

Figure Lengend Snippet: DHRS2 stabilized P53 and decreased p38MAPK phosphorylation. ( a ) The protein levels of p-P53(ser15) and p-Rb(ser795) were determined in DHRS2-V1 and DHRS2-V2-transfected KYSE510 and KYSE30 cells compared with vector control cells. ( b ) The protein levels of p-P53(ser15) and p-Rb(ser795) were determined in DHRS2 knock-down KYSE180 and HKESC1 cells. Tubulin was set as loading control. ( c ) The protein levels of p-p38MAPK, extracellular signal-regulated kinases 1/2 (ERK1/2), MMP2, E-cadherin and β-catenin were determined in DHRS2-V1 and DHRS2-V2-transfected KYSE510 and KYSE30 cells compared with vector control cells. ( d ) The protein levels of p-p38MAPK, ERK1/2, MMP2, E-cadherin and β-catenin were determined in DHRS2 knock-down KYSE180 and HKESC1 cells. GAPDH was set as loading control.

Article Snippet: Antibodies used were: p-P53(ser15) (#9286), p-Rb(ser795) (#9301), p-p38MAPK(Thr180/tyr182) (#9212), extracellular signal-regulated kinases 1/2 (#4695), E-cadherin (#3195), β-catenin (#8481), tubulin (#2128) (Cell Signaling Technology, Danvers, MA, USA), GAPDH (ap7873a) and MMP2 (am1844a) (ABGENT, San Diego, CA, USA), DHRS2 (PA5-25258) (Thermo Fisher Scientific), MDM2 (M4308) (Sigma-Aldrich) and 8-oxoguanine (AB20646) (Abcam, Cambridge, UK). pCDH was bought from System Biosciences (Palo Alto, CA, USA). pCDH-DHRS2-V1 and DHRS2-V2 were constructed and sequenced. pLKO.1-DHRS2-shRNA targeting both variants was bought from Sigma-Aldrich.

Techniques: Transfection, Plasmid Preparation

Journal: Frontiers in Immunology

Article Title: Increased Interleukin-17 and Glucocorticoid Receptor-β Expression in Interstitial Lung Diseases and Corticosteroid Insensitivity

doi: 10.3389/fimmu.2022.905727

Figure Lengend Snippet: Patient characteristics and immunohistochemistry results.

Article Snippet: The slides were immunostained with primary rabbit anti-GR-α (ab3580, Abcam, Cambridge, UK), anti-GR-β (ab233165, Abcam, Cambridge, UK), anti-HDAC2 (ab32117, Abcam, Cambridge, UK), anti-IL-17 A (sc-7927, Santa Cruz, Dallas, TX) and anti-IL-17RA (NBP2-25258, Novus Biologicals, Centennial, CO) antibodies, and incubated overnight at 4°C.

Techniques: Immunohistochemistry, Staining

Journal: Frontiers in Immunology

Article Title: Increased Interleukin-17 and Glucocorticoid Receptor-β Expression in Interstitial Lung Diseases and Corticosteroid Insensitivity

doi: 10.3389/fimmu.2022.905727

Figure Lengend Snippet: Correlations between IL-17 and staining findings (neutrophil counts, IL-17, GR-β, GR-α, GR-β/GR-α, HDAC2).

Article Snippet: The slides were immunostained with primary rabbit anti-GR-α (ab3580, Abcam, Cambridge, UK), anti-GR-β (ab233165, Abcam, Cambridge, UK), anti-HDAC2 (ab32117, Abcam, Cambridge, UK), anti-IL-17 A (sc-7927, Santa Cruz, Dallas, TX) and anti-IL-17RA (NBP2-25258, Novus Biologicals, Centennial, CO) antibodies, and incubated overnight at 4°C.

Techniques: Staining

Journal: Frontiers in Immunology

Article Title: Increased Interleukin-17 and Glucocorticoid Receptor-β Expression in Interstitial Lung Diseases and Corticosteroid Insensitivity

doi: 10.3389/fimmu.2022.905727

Figure Lengend Snippet: IL-17RA expression in ILD lungs. (A) Representative immunohistochemical image of lung specimens from subjects with COP, sarcoidosis and IPF. Magnification ×200. (B, C) Immunohistochemical staining showed no significant difference in IL-17RA expression amongst lung specimens from patients with COP, sarcoidosis and IPF. (D, E) The correlation between IL-17RA expression and IL-17 expression in ILDs. IL-17, interleukin-17; IL-17RA, interleukin-17 receptor A; IPF, idiopathic pulmonary fibrosis; COP, cryptogenic organizing pneumonia; OD, opacity density score; **p < 0.01.

Article Snippet: The slides were immunostained with primary rabbit anti-GR-α (ab3580, Abcam, Cambridge, UK), anti-GR-β (ab233165, Abcam, Cambridge, UK), anti-HDAC2 (ab32117, Abcam, Cambridge, UK), anti-IL-17 A (sc-7927, Santa Cruz, Dallas, TX) and anti-IL-17RA (NBP2-25258, Novus Biologicals, Centennial, CO) antibodies, and incubated overnight at 4°C.

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Frontiers in Immunology

Article Title: Increased Interleukin-17 and Glucocorticoid Receptor-β Expression in Interstitial Lung Diseases and Corticosteroid Insensitivity

doi: 10.3389/fimmu.2022.905727

Figure Lengend Snippet: Correlations between radiographic deterioration and staining findings (neutrophil counts, IL-17, GR-β, GR-α, GR-β/GR-α, HDAC2) in ILDs (COP, sarcoidosis and IPF in combination) and IPF subgroup.

Article Snippet: The slides were immunostained with primary rabbit anti-GR-α (ab3580, Abcam, Cambridge, UK), anti-GR-β (ab233165, Abcam, Cambridge, UK), anti-HDAC2 (ab32117, Abcam, Cambridge, UK), anti-IL-17 A (sc-7927, Santa Cruz, Dallas, TX) and anti-IL-17RA (NBP2-25258, Novus Biologicals, Centennial, CO) antibodies, and incubated overnight at 4°C.

Techniques: Staining

Journal: Frontiers in Immunology

Article Title: Increased Interleukin-17 and Glucocorticoid Receptor-β Expression in Interstitial Lung Diseases and Corticosteroid Insensitivity

doi: 10.3389/fimmu.2022.905727

Figure Lengend Snippet: GR-β up-regulation, HDAC2 down-regulation and corticosteroid insensitivity induced by IL-17. Human fibroblast MRC5 cells were transfected with Si-IL-17RA or scrambled Si-Ctrl and then incubated with IL-17 (10ng/mL). mRNA was determined by RT-qPCR and protein was determined by western blotting. (A, B) Dexamethasone (10 -7 M) reduces collagen I production at both mRNA level (2h) and protein level (6h), but the suppressive effect was hampered by IL-17. Silencing IL-17RA gene restored dexamethasone’s suppressive effect. The GR-β mRNA expression was up-regulated at 2h (C) and protein was increased at 6h and 12h (D) . IL-17 also down-regulated HDAC2 at mRNA and protein level. Silencing IL-17RA gene attenuated IL-17’s effect on GR-β up-regulation and HDAC2 down-regulation. Bars represent means ± SEM of 6 experiments. Si, small interfering RNA; Ctrl, control; IL, interleukin; IL-17RA, interleukin-17 receptor A; Dex, dexamethasone; GR, glucocorticoid receptor; HDAC2, histone deacetylase 2. *p < 0.05.

Article Snippet: The slides were immunostained with primary rabbit anti-GR-α (ab3580, Abcam, Cambridge, UK), anti-GR-β (ab233165, Abcam, Cambridge, UK), anti-HDAC2 (ab32117, Abcam, Cambridge, UK), anti-IL-17 A (sc-7927, Santa Cruz, Dallas, TX) and anti-IL-17RA (NBP2-25258, Novus Biologicals, Centennial, CO) antibodies, and incubated overnight at 4°C.

Techniques: Transfection, Incubation, Quantitative RT-PCR, Western Blot, Expressing, Small Interfering RNA, Histone Deacetylase Assay

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Dissection of FAM20A Expression Across Cell Clusters in Lung Squamous Cell Carcinoma. (A) UMAP visualization showcasing eight distinct cell clusters derived from single-cell sequencing data of lung tissue samples. (B) Dot plot matrix representing the specific marker gene expressions used to identify each cell cluster. The size of the dot indicates the fraction of cells within a cluster expressing the gene, while the color intensity reflects the mean expression level in that cluster. (C) Spatial distribution of FAM20A gene expression across the integrated cell clusters. Predominant expression in the alveolar cluster is indicated (circled). (D) Violin plots illustrating the expression levels of FAM20A in control lung tissues versus LUSC tissues. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A; CLDN18, Claudin 18; CD79A, CD79a Molecule; CLDN5, Claudin 5; CAPS, Calcyphosine; COL1A1, Collagen Type I Alpha 1 Chain; LYZ, Lysozyme; CD3D, CD3d Molecule; EPCAM, Epithelial Cell Adhesion Molecule.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Dissection, Expressing, Derivative Assay, Sequencing, Marker, Gene Expression, Control

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Expression Levels of FAM20A and FAM20C in LUSC. (A) FAM20A expression across various cancers, as sourced from the GTEx database. (B) FAM20C expression across different cancers, derived from the GTEx database. (C) FAM20A expression in 33 cancer types. (D) FAM20C expression in 33 cancer types. (E) Comparison of FAM20A expression in tumor versus normal samples. (F) Differential expression of FAM20C in tumor samples. (G) Box plots comparing FAM20A , FAM20B , and FAM20C expression in patients with and without LUSC. (H) Expression differences of FAM20A , FAM20B , and FAM20C between LUSC samples and matched non-cancerous samples. (I) ROC curve analysis of FAM20A , FAM20B , and FAM20C in normal versus LUSC samples from the TCGA database. (J) qRT-PCR analysis for FAM20A and FAM20C . (K) Western blot results for FAM20A and FAM20C. (L) Immunohistochemistry (IHC) analysis of FAM20A and FAM20C. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Sequence Similarity 20, Member A; FAM20B, Family with Sequence Similarity 20, Member B; FAM20C, Family with Sequence Similarity 20, Member C; ACC, Adrenocortical carcinoma; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangiocarcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute myeloid leukemia; LGG, Brain lower grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin cutaneous melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular germ cell tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine corpus endometrial carcinoma; UCS, Uterine carcinosarcoma; UVM, Uveal melanoma. ns: not significant difference.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Expressing, Derivative Assay, Comparison, Quantitative Proteomics, Quantitative RT-PCR, Western Blot, Immunohistochemistry, Sequencing

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Clinical characteristics of the LUSC patients.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Survival Analysis in LUSC Based on FAM20A and FAM20C. Utilizing the GEPIA2 tool, overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in LUSC were analyzed in relation to the expression of FAM20A and FAM20C, with survival plots provided. Significance levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A; FAM20C, Family with Sequence Similarity 20, Member C; GEPIA2, Gene Expression Profiling Interactive Analysis 2; OS, Overall survival; DSS, Disease-specific survival; PFI, Progression-free interval.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Expressing, Sequencing, Gene Expression

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Association of FAM20A and FAM20C levels with Clinical Pathological Traits in LUSC. (A) Overall survival, (B) Disease specific survival and (C) Progress Free interval of FAM20A mRNA levels. (D) Overall survival, (E) Disease specific survival and (F) Progress Free interval of FAM20C mRNA levels. Significant levels indicated as * P <0.05, ** P <0.01, *** P <0.001. LUSC, Lung squamous cell carcinoma; Fam20A, Family with Squance Similarity 20, member A; Fam20C, Family with Squance Similarity 20, member C.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques:

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: Nomogram Predictions and Calibration for LUSC Patients. A nomogram predicting the first-year, three-year, and five-year outcomes for (A) OS, (B) DSS, (C) and PFI. Calibration plots (D-F) for OS, DSS, and PFI validate the predictive accuracy of the nomogram. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A; OS, Overall survival; DSS, Disease-specific survival; PFI, Progression-free interval.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Sequencing

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: FAM20A and Its Correlation with Oncogenes. (A) Analysis of FAM20A ’s correlation with various oncogenes. The correlation of FAM20A with (B) BRCA1 , (C) BRCA2 , (D) RAD51 , (E) CTLA4 , and (F) CD80 . FAM20A, Family with Sequence Similarity 20, Member A; FGR, Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog; CFH, Complement factor H; FUCA2, Alpha-L-fucosidase 2; GCLC, Glutamate-cysteine ligase catalytic subunit; NFYA, Nuclear transcription factor Y subunit alpha; CTLA4, Cytotoxic T-lymphocyte associated protein 4; BRCA1, Breast Cancer 1 DNA repair associated; BRCA2, Breast Cancer 2 DNA repair associated; RAD51, Radiation sensitive 51 recombinase; LDHA, Lactate dehydrogenase A; LDHB, Lactate dehydrogenase B; PKM, Pyruvate kinase M1/2; GYG1, Glycogenin 1; TP53, Tumor protein p53; EGFR, Epidermal growth factor receptor; KRAS, Kirsten Rat Sarcoma proto-oncogene, GTPase.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Sequencing

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: FAM20A and Immune Infiltration in LUSC. (A) Analysis of the relationship between FAM20A expression and immune infiltration levels in LUSC, using TIMER databases. (B) Correlation between FAM20A expression and 24 immune cell types in LUSC tissues, as per TCGA data. (C) Correlation analysis in LUSC tissues from GTEx data. (D) Cumulative survival analysis of LUSC patients considering immune cell presence and FAM20A levels. Significance levels indicated as * P <0.05, *** P <0.001. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A; TIMER, Tumor Immune Estimation Resource; TCGA, The Cancer Genome Atlas; DC, Dendritic cells; iDC, Immature dendritic cells; pDC, Plasmacytoid dendritic cells; Tcm, Central memory T cells; Tem, Effector memory T cells; TFH, Follicular helper T cells; aDC, Activated dendritic cells; Tgd, Gamma delta T cells; NK cells, Natural killer cells; Treg, Regulatory T cells.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Expressing, Sequencing

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: DNA Methylation of FAM20A in LUSC. (A) A heatmap depicting FAM20A DNA methylation expression levels in LUSC, using the MethSurv platform. (B) Prognostic significance of FAM20A cg24064639 methylation in LUSC. (C) Violin plots comparing methylation levels across different age groups. (D) Methylation level density distribution. LUSC, Lung squamous cell carcinoma; FAM20A, Family with Sequence Similarity 20, Member A.

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: DNA Methylation Assay, Expressing, Methylation, Sequencing

Journal: Frontiers in Immunology

Article Title: FAM20A : a potential diagnostic biomarker for lung squamous cell carcinoma

doi: 10.3389/fimmu.2024.1424197

Figure Lengend Snippet: GSEA analysis of LUSC in FAM20A expression groups. Gene set enrichment analysis (GSEA) conducted on LUSC transcriptomic data from the TCGA database (A) . Eight of these pathways, pertinent to the tumor microenvironment, including the Nkt Pathway (B) , Chemokine Receptors Bind Chemokines (C) , Cancer Immunotherapy by PD1 Blockade (D) , Cancer Immunotherapy by CTLA-4 Blockade (E) , Interleukin 2 Family Signaling (F) , Amb2 Neutrophils Pathway (G) , Toll-Like Receptor Cascades (H) , Interferon Signaling (I) .

Article Snippet: The sections were incubated with FAM20A (1:50, Cat. No. 25258–1-AP, Proteintech, USA) antibody overnight at 4°C.

Techniques: Expressing